S&P 500 Futures
(0.10%) 5 332.50 points

Dow Jones Futures
(0.03%) 40 148 points

Nasdaq Futures
(0.14%) 18 662 points

Oil
(-0.09%) $79.99

Gas
(0.65%) $2.64

Gold
(1.08%) $2 443.40

Silver
(2.79%) $32.13

Platinum
(0.38%) $1 094.10

USD/EUR
(-0.02%) $0.920

USD/NOK
(-0.07%) $10.67

USD/GBP
(0.01%) $0.787

USD/RUB
(-0.26%) $90.73

Realtime updates for Pliant Therapeutics Inc [PLRX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

BUY

66.67%
return 5.24%

SELL

28.57%
return 3.07%

Last Updated17 May 2024 @ 16:00

25% discount on Stockinvest.us - Use code: Podcast

-2.18% $ 15.27

BUY 137542 min ago

@ $16.43

Issued: 14 Feb 2024 @ 15:44

Return: -7.03%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 5.47 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States...

Stats
Today's Volume	359 306
Average Volume	372 731
Market Cap	921.17M
EPS	$0 ( 2024-05-14 )
Next earnings date	( $-0.850 ) 2024-08-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.34
ATR14	$0.0160 (0.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-02	Cummings Keith Lamont	Buy	21 000	Common Stock
2024-05-02	Cummings Keith Lamont	Sell	21 000	Stock Option (Right to Buy)
2024-01-23	Lefebvre Eric	Buy	42 900	Common Stock
2024-01-23	Lefebvre Eric	Buy	85 800	Stock Option (Right to Buy)
2024-01-23	Hull Hans	Buy	31 500	Common Stock

INSIDER POWER
63.16
Last 98 transactions
Buy: 2 171 292 \| Sell: 573 083

Volume Correlation

Long: -0.14 (neutral)

Short: 0.86 (strong)

Signal:(58.864) Same movement expected

Pliant Therapeutics Inc Correlation

10 Most Positive Correlations
ATLC	0.932
CWCO	0.931
MRTN	0.929
NDLS	0.924
AKTX	0.919
BCOV	0.919
HTLD	0.918
CARE	0.916
CNXC	0.914
ADTN	0.913

10 Most Negative Correlations
MTEK	-0.904
JVA	-0.894
SWAV	-0.894
RZLT	-0.887
IMPPP	-0.883
VNOM	-0.881
FTGC	-0.879
GHRS	-0.878
ARYD	-0.877
APXI	-0.877

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pliant Therapeutics Inc Correlation - Currency/Commodity

-0.81
( strong negative )

-0.79
( moderate negative )

0.00
( neutral )

-0.74
( moderate negative )

-0.03
( neutral )

0.55
( weak )

Pliant Therapeutics Inc Financials

Annual	2023
Revenue:	$1.58M
Gross Profit:	$-261 000 (-16.52 %)
EPS:	$-2.75

FY	2023
Revenue:	$1.58M
Gross Profit:	$-261 000 (-16.52 %)
EPS:	$-2.75

FY	2022
Revenue:	$9.69M
Gross Profit:	$6.00M (61.99 %)
EPS:	$-2.89

FY	2021
Revenue:	$7.57M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.71

Financial Reports:

No articles found.

Pliant Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.